The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease (IBD): A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

ABSTRACT The treatment goal for children suffering from inflammatory bowel disease (IBD) has been evolving with biologic therapies like anti-TNF agents assuming a more central role in treatment of more aggressive and extensive phenotype. Earlier introduction of anti-TNF agents have shown to be more effective and may even alter the natural history of IBD. However, development of anti-drug antibodies (ADA) limits long term usage and leads to dose adjustment in almost half of patients treated with these medications. One of the strategies to minimize the development of ADA has been concomitant use of immunomodulator (IM) medications, resulting in fewer infusion reactions and sustained trough levels, potentially lowering the need for dose adjustments. However, balanced with these benefits of optimized dosing and likely more sustained response, is the concern about increased risk of complications, such as infections and malignancies. The current manuscript reviews the available pediatric literature regarding efficacy, safety and side effect profile of combination (IM and biologics) therapy in pediatric Crohn's disease and ulcerative colitis, with particular emphasis on cost constraints, and recommendations for selection of patients who would benefit most from combination therapy. Address correspondence and reprint requests to Professor Andrew S. Day, Department of Paediatrics, University of Otago, Christchurch, P.O. Box 4345, Christchurch, 8140, New Zealand (e-mail: andrew.day@otago.ac.nz). Received 28 June, 2016 Accepted 17 November, 2017 The authors report no conflicts of interest. © 2017 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2nAXntH
via IFTTT